Henk Doude van Troostwijk
Corporate Officer/Principal bij HANSA BIOPHARMA AB
Actieve functies van Henk Doude van Troostwijk
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| HANSA BIOPHARMA AB | Corporate Officer/Principal | 01-06-2019 | - |
Loopbaan van Henk Doude van Troostwijk
Eerdere bekende functies van Henk Doude van Troostwijk
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Raptor Pharmaceuticals Corp.
 Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Corporate Officer/Principal | - | - |
Genzyme Europe BV
 Genzyme Europe BV Pharmaceuticals: MajorHealth Technology Part of Sanofi, Genzyme Europe BV is a Dutch company that develops and manufactures pharmaceutical and biotherapeutic products. The company is based in Amsterdam, Netherlands. | Corporate Officer/Principal | - | - |
| RAPTOR PHARMACEUTICAL CORP | Corporate Officer/Principal | 15-04-2012 | - |
Opleiding van Henk Doude van Troostwijk
| Henley Management College | Masters Business Admin |
Statistieken
Internationaal
| Verenigde Staten | 3 |
| Zweden | 2 |
| Verenigd Koninkrijk | 2 |
Operationeel
| Corporate Officer/Principal | 4 |
| Masters Business Admin | 1 |
Sectoraal
| Health Technology | 5 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| HANSA BIOPHARMA AB | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Horizon Pharmaceutical LLC
 Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Horizon Pharmaceutical LLC engages in the development of transformative treatments for people affected by rare and debilitating diseases. It offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults and for six years and older children. The company was founded by Christopher M. Starr and Todd C. Zankel on April 29, 2002 and is headquartered in Novato, CA. | Health Technology |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Health Technology |
Genzyme Europe BV
Genzyme Europe BV Pharmaceuticals: MajorHealth Technology Part of Sanofi, Genzyme Europe BV is a Dutch company that develops and manufactures pharmaceutical and biotherapeutic products. The company is based in Amsterdam, Netherlands. | Health Technology |